Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

William C N Dunlop

Showing results (1-10 of 13) with videos related to

Pageof 2
Sort By:
Advances in Therapy|June 19, 2017
When Science is Not Enough: A Framework Towards More Customer-Focused Drug DevelopmentNektarios Oraiopoulos, William C N Dunlop
Advances in Therapy|September 7, 2015
The Budget Impact of Biosimilar Infliximab (Remsima®) for the Treatment of Autoimmune Diseases in Five European CountriesAshok Jha, Alex Upton, William C N Dunlop, et al.
Health Policy (Amsterdam, Netherlands)|March 24, 2018
Innovative pharmaceutical pricing agreements in five European markets: A survey of stakeholder attitudes and experienceWilliam C N Dunlop, Alexandra Staufer, Pierre Levy, et al.
Journal of Medical Economics|April 14, 2016
Examining the association between pain severity and quality-of-life, work-productivity loss, and healthcare resource use among European adults diagnosed with painEdward A Witt, James Kenworthy, Gina Isherwood, et al.
Value in Health : the Journal of the International Society for Pharmacoeconomics and Outcomes Research|April 23, 2018
Cost-Effectiveness of Take-Home Naloxone for the Prevention of Overdose Fatalities among Heroin Users in the United KingdomSue Langham, Antony Wright, James Kenworthy, et al.
Cancer Management and Research|November 19, 2021
The Impasse on Overall Survival in Oncology Reimbursement Decision-Making: How Can We Resolve This?Michael Patrick Lux, Oriana Ciani, William C N Dunlop, et al.
Addiction Science & Clinical Practice|February 26, 2017
A systematic review of health economic models of opioid agonist therapies in maintenance treatment of non-prescription opioid dependenceMersha Chetty, James J Kenworthy, Sue Langham, et al.
Journal of Medical Economics|June 9, 2018
Cost-effectiveness modeling for neuropathic pain treatments: investigating the relative importance of parameters using an open-source modelMatthew Hirst, Matthew W Bending, Gianluca Baio, et al.
Journal of Medical Economics|May 11, 2017
Use of opioid substitution therapies in the treatment of opioid use disorder: results of a UK cost-effectiveness modelling studyJames Kenworthy, Yunni Yi, Antony Wright, et al.
The European Journal of Health Economics : HEPAC : Health Economics in Prevention and Care|May 14, 2018
Cost-utility analysis of an intervention designed to reduce the critical handling error of insufficient inspiratory effortRebecca Forster, Aran Ratcliffe, Megan Lewis, et al.
Pageof 2

Showing results (1-10 of 13) with videos related to

Sort By:
Pageof 2
Advances in Therapy|June 19, 2017
When Science is Not Enough: A Framework Towards More Customer-Focused Drug DevelopmentNektarios Oraiopoulos, William C N Dunlop
Advances in Therapy|September 7, 2015
The Budget Impact of Biosimilar Infliximab (Remsima®) for the Treatment of Autoimmune Diseases in Five European CountriesAshok Jha, Alex Upton, William C N Dunlop, et al.
Health Policy (Amsterdam, Netherlands)|March 24, 2018
Innovative pharmaceutical pricing agreements in five European markets: A survey of stakeholder attitudes and experienceWilliam C N Dunlop, Alexandra Staufer, Pierre Levy, et al.
Journal of Medical Economics|April 14, 2016
Examining the association between pain severity and quality-of-life, work-productivity loss, and healthcare resource use among European adults diagnosed with painEdward A Witt, James Kenworthy, Gina Isherwood, et al.
Value in Health : the Journal of the International Society for Pharmacoeconomics and Outcomes Research|April 23, 2018
Cost-Effectiveness of Take-Home Naloxone for the Prevention of Overdose Fatalities among Heroin Users in the United KingdomSue Langham, Antony Wright, James Kenworthy, et al.
Cancer Management and Research|November 19, 2021
The Impasse on Overall Survival in Oncology Reimbursement Decision-Making: How Can We Resolve This?Michael Patrick Lux, Oriana Ciani, William C N Dunlop, et al.
Addiction Science & Clinical Practice|February 26, 2017
A systematic review of health economic models of opioid agonist therapies in maintenance treatment of non-prescription opioid dependenceMersha Chetty, James J Kenworthy, Sue Langham, et al.
Journal of Medical Economics|June 9, 2018
Cost-effectiveness modeling for neuropathic pain treatments: investigating the relative importance of parameters using an open-source modelMatthew Hirst, Matthew W Bending, Gianluca Baio, et al.
Journal of Medical Economics|May 11, 2017
Use of opioid substitution therapies in the treatment of opioid use disorder: results of a UK cost-effectiveness modelling studyJames Kenworthy, Yunni Yi, Antony Wright, et al.
The European Journal of Health Economics : HEPAC : Health Economics in Prevention and Care|May 14, 2018
Cost-utility analysis of an intervention designed to reduce the critical handling error of insufficient inspiratory effortRebecca Forster, Aran Ratcliffe, Megan Lewis, et al.
Pageof 2